Andera Partners

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.